Atopic Dermatitis (Eczema)
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (Eczema) (BREEZE-AD3)
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis (eczema).
Your participation could last up to 108 weeks and include up to 17 visits to the study center.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have met participation requirements for a previous atopic dermatitis (eczema) study
- Participants must have completed the final treatment visit in a previous baricitinib atopic dermatitis (eczema) study
- Participants must not have permanently stopped taking baricitinib during a previous baricitinib study